Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Public ClinicalTrials.gov record NCT04487860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Study identification
- NCT ID
- NCT04487860
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Industry
- Enrollment
- 327 participants
Conditions and interventions
Conditions
Interventions
- AS012 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2021
- Primary completion
- May 19, 2022
- Completion
- Feb 26, 2023
- Last update posted
- Mar 9, 2025
2021 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sun Pharma Site 15 | Phoenix | Arizona | 85018 | — |
| Sun Pharma Site 02 | Bryant | Arkansas | 72022 | — |
| Sun Pharma Site 09 | Fremont | California | 94538 | — |
| Sun pharma site 30 | Los Angeles | California | 90036 | — |
| Sun Pharma Site 01 | Brandon | Florida | 33511. | — |
| Sun Pharma Site 06 | Fort Lauderdale | Florida | 33308 | — |
| Sun Pharma Site 04 | Miami | Florida | 33175 | — |
| Sun Pharma Site 05 | Miramar | Florida | 33027 | — |
| Sun Pharma Site 10 | Ormond Beach | Florida | 32174 | — |
| Sun Pharma Site 14 | West Lafayette | Indiana | 47906 | — |
| Sun Pharma Site 12 | Baton Rouge | Louisiana | 70809 | — |
| Sun Pharma Site 13 | New Orleans | Louisiana | 70115 | — |
| Sun pharma site 31 | Boston | Massachusetts | 02111 | — |
| Sun Pharma Site 07 | Troy | Michigan | 48084 | — |
| Sun Pharma Site 29 | East Greenwich | Rhode Island | 02818 | — |
| Sun Pharma Site 08 | Warwick | Rhode Island | 02886 | — |
| Sun Pharma Site 03 | Dallas | Texas | 75234 | — |
| Sun Pharma Site 16 | Pflugerville | Texas | 78660 | — |
| Sun Pharma Site 11 | Mill Creek | Washington | 98012 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04487860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04487860 live on ClinicalTrials.gov.